

161th SEIAA, A.P.



**AGENDA NOTES FOR THE 161th MEETING OF STATE LEVEL
ENVIRONMENT IMPACT ASSESSMENT AUTHORITY (SEIAA)
A.P., TO BE HELD 28.08.2021 AT VIJAYAWADA,
AP.
(video conference)**

Present:

31/08/2021

The following members were present:

1.	Sri P.Venkata Rami Reddy, I.A.S, (Retired).	Chairman
2.	Dr. Thatiparthi Byragi Reddy Professor. Department of Environmental Sciences, Andhra University, Visakhapatnam	Member
3.	Dr. P.V.ChalapathiRao, I.F.S Special Secretary to Govt., Environment, Forests, Sciences and Technology Department, Govt. of Andhra Pradesh & Member Secretary, SEIAA,A.P.	Member Secretary

164.02 & 161.01	Proposed to establish Bulk Drugs Manufacturing Unit by M/s.SR Qualichem Plot Nos.: 61 to 66, Industrial Park, Tirumalagiri Village, Jaggayyapeta Mandal, Krishna District, Andhra Pradesh (SIA/AP/IND2/199463/2021)
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of M/s. SR Qualichem., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 16 TPM. The representative of the project proponent and their Consultant M/s. Rightsource Industrial Solutions Pvt. Ltd have attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020.Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021.</p> <p>The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 16 TPM.</p> <p>The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 16 TPM. Further the Committee advised to procure more land taking the total area of land to with a minimum of 2 Acres.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.03 & 161.02	Proposal of establishment of Bulk Drugs Manufacturing unit by M/s. MRR Labs Private Limited at Sy. Nos.: 320-14 & 320-15, Bhimolu Village Gopalapuram Mandal, West Godavari District, Andhra Pradesh SIA/AP/IND2/199862/2021
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p>

	<p>The Proposal of M/s. MRR Labs Private Limited., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 285.0 TPM. The consultant M/s. Right Source Industrial Solutions Pvt Ltd & Managing Director have attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020.Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 285.0 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 285.0 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.04 & 161.03	<p>Proposal of establishment of Bulk Drugs manufacturing unit by M/s. Tibro Pharmaceuticals Private Limited, Located at Survey No: 320-26, Bhimolu Village, Gopalapuram Mandal, West Godavari District, Andhra Pradesh SIA/AP/IND2/199875/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021: Category : B2-5(f)-API The Proposal of M/s. Tibro Pharmaceuticals Private Limited., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 215.0 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020.Further extended up to 31st December, 2021 vide</p>

	<p>S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 215.0 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 215.0 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.05 & 161.04	<p>Proposal of establishment of Active Pharma Ingredients Manufacturing unit by M/s. KVR Drugs Private Limited at Sy. Nos.: 320-16 & 320-19, Bhimolu (V), Gopalapuram (M), West Godavari (D), Andhra Pradesh SIA/AP/IND2/199837/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021: Category : B2-5(f)-API The Proposal of KVR Drugs Private Limited., is for Environmental Clearance for production quantities of the Manufacturing of API Products – 276.0 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised, as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" And extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No.2859(E), dated 16.07.2021.</p> <p>The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 276.0 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for</p>

	<p>manufacture of Bulk Drug and Intermediates with production quantity – 276.0 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.06 & 161.05	<p>Proposal of establishment of Bulk Drugs manufacturing unit by M/s. Manaar Labs Private Limited, Sy. No.: 248, Vedadri Village, Jaggayyapeta Mandal, Krishna District, Andhra Pradesh. SIA/AP/IND2/202674/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of Manaar Labs Pvt. Ltd., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 96 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006-Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 96 TPM.</p> <p>The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 96 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.07 & 161.06	<p>Proposal of establishment of Bulk Drugs manufacturing unit by M/s. SGR QUALICHEM, RS. No's.: 10/1 & 10/3, Pochampally Village, Jaggayyapeta Mandal, Krishna District, Andhra Pradesh. SIA/AP/IND2/202998/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of SGR Qualichem., is for Environmental Clearance for production</p>

	<p>quantities of the bulk drug & Intermediates – 60 TPM. The representative of the project proponent and their Consultant M/s. Rightsource Industrial Solutions Pvt. Ltd have attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006-Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 60 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 60 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
<p>164.08 & 161.07</p>	<p>Proposed Establishment of Active Pharmaceutical Ingredients (APIs) and API Intermediates Manufacturing unit along with R&D Products by M/s. Bhagyanagar Laboratories Private Limited, t Sy. No. 39 & 44, Chityala (V), Gopalapuram (M), West Godavari district of Andhra Pradesh SIA/AP/IND2/202905/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of M/s. Bhagyanagar Laboratories Private Limited., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 63.15 TPM.</p> <p>The representative of the project proponent and their Consultant, M/s. KKB Envirocare Consultants Private Limited has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the</i></p>

	<p><i>provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020.Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 63.15 TPM. The project proponent has submitted the EMP, PFR, and Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 63.15 TPM duly stipulating a condition that the project proponent shall tie-up with the nearby TSDF for treatment and disposal of hazardous waste and submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.09 & 161.08	<p>Proposed to establish Bulk Drugs & Drug Intermediates Manufacturing Unit by M/s. Lakshmi SARAS Chem Tech Pvt. Ltd, R.S. Nos.: Part of 3/1 & 3/3, Pochampally Village, Jaggayyapeta Mandal, Krishna District, Andhra Pradesh SIA/AP/IND2/203515/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021: Category : B2-5(f)-API The Proposal of Lakshmi Saras Chem Tech Pvt. Ltd., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 70 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020.Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 70.0 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment</p>

	<p>Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities.</p> <p>The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 70.0 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.10 & 161.09	<p>Proposed to establish Bulk Drugs & Drug Intermediates Manufacturing Unit by M/s. Ergam Life Sciences Pvt. Ltd, Survey No.: 917-B-2-1, Veldurthy Village & Mandal, Guntur District, Andhra Pradesh SIA/AP/IND2/203779/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of Ergam Life Sciences Pvt. Ltd., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 10 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 10 TPM.</p> <p>The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 10 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>

164.11 & 161.10	Paper Sizing Formulation Chemicals Manufacturing Unit by M/s. IVAX Paper Chemicals Limited. , at Sy. Nos.: 11, 16 & 18P, Gumpam village, Pusapatirega Mandal, Vizianagaram District, Andhra Pradesh SIA/AP/IND2/204046/2021
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2</p> <p>The Proposal of M/s. IVAX Paper Chemicals Limited., is for Environmental Clearance for production quantities of AKD Wax Emulsion – 1000 MT/Month, Akenyl Succinic Anhydride (ASA) - 200 MT/Month, Starch Based Products - 300 MT/Month & Rosin Based Products – 1875 MT/Month. The project proponent and their consultant, M/s.KKB Envirocare Consultants Pvt. Ltd have attended the meeting. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates).</p> <p>The Committee noted that this is a paper sizing chemicals (mixing & blending) unit, the PP has proposed the paper sizing chemicals (mixing & blending) unit with production capacity: 3375 MT/Month. The project proponent has submitted the EMP, PFR, Risk Assessment Reports. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of AKD Wax Emulsion – 1000 MT/Month, Akenyl Succinic Anhydride (ASA) - 200 MT/Month, Starch Based Products - 300 MT/Month & Rosin Based Products – 1875 MT/Month.</p> <p>Decision of SEIAA:Refer to SEAC to examine the jurisdiction of SEIAA, A.P.</p> <p><i>As per the minutes of SEAC the proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates) and as per the MoEF&CC Office Memorandum dated 13.04.2020, All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects. Hence the jurisdiction of the proposal may be examined.</i></p>
164.12 & 161.11	Proposed to establish Bulk Drugs & Drug Intermediates Manufacturing Unit by M/s. Octanex Life Sciences Pvt. Ltd. Sy. No.: 75, Vedadri Village, Jaggayyapeta Mandal, Krishna District, Andhra Pradesh SIA/AP/IND2/204085/2021
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of M/s. Octanex Life Sciences Pvt. Ltd., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 150 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to</i></p>

	<p><i>the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time."</i> and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 150 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 150 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
<p>164.13 & 161.12</p>	<p>Proposed to establish Bulk Drugs & Drug Intermediates Manufacturing Unit by M/s. Srimaan Formulations Pvt. Ltd, Survey No's.: 201, 201-1A, 201-1B & 201- 5, Peddaravipadu Village, Mundlamuru Mandal, Prakasam District, Andhra Pradesh SIA/AP/IND2/204483/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021: Category : B2-5(f)-API The Proposal of M/s. Srimaan Formulations Pvt. Ltd., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 250 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time."</i> Further it is extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 250TPM. The</p>

	<p>project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 250 TPM.</p> <p>Decision of SEIAA Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
<p>164.14 & 161.13</p>	<p>Proposed to establish Bulk Drugs & Drug Intermediates Manufacturing Unit by M/s. Sumitra Labs, at Plot No.: 50A, APIIC, YSR Jagananna Mega- Industrial Hub – Kopparthy, Yadavapuram Village, Vallur Mandal, YSR Kadapa District, Andhra Pradesh SIA/AP/IND2/204509/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021: Category : B2-5(f)-API The Proposal of M/s. Sumitra Labs., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 65 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" Further it is extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 65TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 65 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC.</p>

	Recommended for issue of Environmental Clearance.
164.15 & 161.14	Proposed to establish Bulk Drugs & Drug Intermediates Manufacturing Unit by M/s. SNR Pharma at Plot No.: 49, APIIC, YSR Jagananna Mega- Industrial Hub – Kopparthi, Yadavapuram Village, Vallur Mandal, YSR Kadapa District, Andhra Pradesh SIA/AP/IND2/204745/2021
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of M/s. SNR Pharma., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 80 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" Further it is extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 80 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 80 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.16 & 161.15	Proposed to establish Bulk Drugs & Drug Intermediates Manufacturing Unit by M/s. Ajay Labs Pvt. Ltd., Unit-II, R. S. No.: 11/2C, Pochampally Village, Jaggaihpeta Mandal, Krishna District, Andhra Pradesh. SIA/AP/IND2/204088/2021
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of M/s. Ajay Labs Pvt. Ltd., Unit - II is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 100</p>

	<p>TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" Further it is extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021.</p> <p>The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 100 TPM.</p> <p>The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 100 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.17 & 161.16	<p>Establishment of API (Bulk Drugs and Intermediates) Manufacturing Unit of capacity 168 TPM by M/s. RDL Labs Pvt. Ltd., Plot No.48a, Ysr Jagananna Mega Industrial Hub, Koppaathy, Sy.No.22pt, Yadavapuram Village, Vallur Revenue Mandal, YSR Kadapa District, Andhra Pradesh SIA/AP/IND2/205460/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of M/s. RDL Labs Pvt. Ltd., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 168 TPM. The project proponent and their consultant M/s. Team Labs and Consultants have attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021.</p>

	<p>The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 168 TPM.</p> <p>The project proponent has submitted the EMP, PFR, and Risk Assessment Reports. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 168 TPM duly stipulating a condition that the project proponent shall submit an undertaking that they allocate funds of 2% of the project cost as a part of CER activity.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.18 & 161.17	<p>Proposal of establishment of Bulk Drugs manufacturing unit by M/s. Astraind Chemicals Pvt. Ltd at Survey No. 25/2B1 & 25/2B2, Gauravaram Village, Jaggaiahpetta Mandal, Krishna District, Andhra Pradesh SIA/AP/IND2/205648/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of Astraing Chemicals Pvt. Ltd., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 60.0 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting.</p> <p>MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 60.0 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and</p>

	<p>deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 60.0 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.19 & 161.18	<p>Proposal of establishment of Bulk Drugs manufacturing unit by M/s. Eamani Pharma Laboratories Pvt. Ltd at Survey No. 4/1A, 4/1B, 4/1C & 4/2A, Pochampally Village, Jaggaiahpetta Mandal, Krishna District, Andhra Pradesh SIA/AP/IND2/204992/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2-5(f)-API</p> <p>The Proposal of M/s. Eamani Pharma Laboratories Pvt. Ltd., is for Environmental Clearance for production quantities of the bulk drug & Intermediates – 200 TPM. The project proponent and their consultant M/s. Right Source Industrial Solutions Pvt Ltd has attended the meeting. MoEF&CC, GoI, New Delhi issued notification vide S.O. No. 1223(E), dated 27.03.2020 and MoEF&CC Office Memorandum dated 13.04.2020, wherein " <i>All proposals for projects or activities in respect of Active Pharmaceutical Ingredients (API), received up to the 30th September 2020, shall be appraised , as Category 'B2' projects provided that any subsequent amendment or expansion or change in product mix, after the 30th September 2020, shall be considered as per the provisions in force at that time.</i>" and extended up to 30th March, 2021 vide S.O. No. 3636(E), dated 15.10.2020. Further extended up to 31st December, 2021 vide S.O. No. 2859(E), dated 16.07.2021. The proposed project falls under Item 5(f) of the schedule of the EIA Notification 2006- Synthetic organic chemicals industry (dyes & dye intermediates & bulk drug and intermediates). The Committee noted that this is a bulk drug & intermediates manufacturing unit. Now, the PP has proposed the Bulk Drug & Intermediates manufacturing unit with production capacity: 200 TPM. The project proponent has submitted the EMP, PFR, Risk Assessment Reports, affidavit for TSDF Membership, affidavit for CER budget allocation and activities. The project proponent has submitted an affidavit on the drugs proposed to be manufactured and informed to the committee that, the drugs are related to the symptoms of the ailments like Covid 19 and other post-Covid symptoms. The Committee after examining the project proposals, presentations and deliberations recommended for issue of Environmental Clearance for manufacture of Bulk Drug and Intermediates with production quantity – 200 TPM.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>
164.20 & 161.19	<p>Construction of Residential Apartment Building of by M/s. SBNE URBAN PROPERTIES LLP at Sy. 336, (P), & 382, Tarakarama Nagar Satellite Township, Rushikonda layout of VUDA, Madhurawada village, Visakhapatnam (Rural) Mandal Visakhapatnam District, Andhra Pradesh - Environmental Clearance –</p>

	Reg. SIA/AP/MIS/200739/2021
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2</p> <p>The proponent and their consultant, M/s. Pioneer Enviro Laboratories & consultants Pvt ltd. have attended the meeting. The Committee noted that the project proponent proposes for construction of Residential building project in the site area of 9,539.82 Sq.mt (2.35 Acres) and built up area is 53,775.60 Sq.m Further the Committee noted that the proposed project falls under Item 8(a) of the schedule of the EIA Notification 2006- Construction projects , as the proposed project site covering an area is < 50 ha and built up area is <1,50,000 sq. m. The present proposal comes under category ‘B2’ project. The Committee after examining the project proposals, presentations, MoEF&CC’ Notifications & OMs and detailed deliberations, recommended for issue of Environmental Clearance duly stipulating a condition that the project proponent shall provide STP for the treatment and disposal of domestic effluents; dual pipeline plumbing system.</p> <p>Decision of SEIAA:- Refer to SEAC to examine w.r.t Eco-sensitive Zone notification of Kambalakonda Wildlife Sanctuary.</p>
164.21 & 161.20	<p>Construction of Residential Apartment Building of by M/s. SREE BALAJEE NIRMAN & ESTATES LLP (Residential cum Mall cum Multiplex complex) at Sy. No. 1/3, 41/1, 41/2, of Kapparada Village, 58/1, 59/1, 59/2 of Marripalem Village, Visakhapatnam (Urban) Mandal, Visakhapatnam District, Andhra Pradesh – Environmental Clearance –Reg SIA/AP/MIS/200056/2021</p>
	<p>Recommendations of the SEAC on 26.07.2021:</p> <p>Category : B2</p> <p>The proponent and their consultant, M/s. Pioneer Enviro Laboratories & consultants Pvt ltd. have attended the meeting. The Committee noted that the project proponent proposes for construction of Residential building project in the site area of 14,120.20 Sq.m and built up area is 79,823.83 Sq.m Further the Committee noted that the proposed project falls under Item 8(a) of the schedule of the EIA Notification 2006- Construction projects , as the proposed project site covering an area is < 50 ha and built up area is <1,50,000 sq. m. The present proposal comes under category ‘B2’ project. The Committee after examining the project proposals, presentations, MoEF&CC’ Notifications & OMs and detailed deliberations, recommended for issue of Environmental Clearance duly stipulating a condition that the project proponent shall provide STP for the treatment and disposal of domestic effluents; dual pipeline plumbing system.</p> <p>Decision of SEIAA:- Agreed with the recommendation of the SEAC. Recommended for issue of Environmental Clearance.</p>

Special Secretary To Govt

Dr. P.V.Chalapathi Rao, I.F.S Dr. Thatiparthi Byragi Reddy

Sri P.Venkata Rami
Reddy, I.A.S,
(Retired).

Special Secretary to Govt., Professor. Department of
Environment, Forests, Sciences Environmental Sciences, Andhra
and Technology Department, University, Visakhapatnam
Govt. of Andhra Pradesh &
Member Secretary,
SEIAA,A.P.

Chairman,
SEIAA,A.P